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Abstract  
The discovery and development of new breast cancer treatments is vital as current 
therapies, both targeted and non-targeted have been shown to have toxic side effects and 
cancers have become resistant to the treatment. The pursuit of new appropriate therapies 
can be directed towards naturally occurring proteins or peptides found present in nature 
such as venomous secretions.  Understanding where and how breast cancer management 
started and where it currently stands is key in avoiding failure and covering as many avenues 
as possible. Although there are a variety of treatment strategies available, breast cancer 
management is still limited in terms of survival and prognosis. Understanding what those 
limits are and how they affect treatment response is relevant for future clinical trials. The 
present review focused on targeted and non-targeted therapies, molecular cancer subtypes 
and available alternatives for drug development in breast cancer. Among notable 
alternatives for drug development, venoms are now being utilised in drug discovery research 
due to their rich variety of small peptides, organic and inorganic compounds. With an 
estimated 12 million peptides awaiting identification and characterisation, venoms are a 
collection of diverse and attractive drug development platforms.  Currently there have been 
a number of preliminary studies undertaken using venom and cultured human cancer cells, 
but more research is needed, not only to inform on the effects, but the need for more 
research is as relevant as ever, in order to identify as many venom compounds as possible. 
This paper will report a number of these studies. 
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Introduction  
With a list of six FDA approved drugs, venom-based drug discovery is a relevant field 
of research for future anti-cancer therapies. Studying and identifying toxins, peptides and 
other compounds from venomous animals will improve our knowledge of the potential of 
these naturally occurring peptides against human cancer cells. 
Methods 
The following work investigates the effects of three types of venom Acanthoscurria 
geniculata (A. gen), Heterometrus swammerdami (H. swa) and Naja Naja (N Naja) on the 
human breast cancer cell line MDA-MB-468 using SDS-PAGE and analysing protein 
expression – Epidermal Growth Factor Receptor. This investigation will also report the 
results of using A gen. venom fractions on MDA-MB-468, which overexpresses EGFR, the 
first member of the Epidermal Growth Factor Receptor family of tyrosine kinases using HPLC, 
SDS-PAGE and Western Blot methods. Using the venom from the above species on human 
phospho-array blots, the effects the types of venom have on phosphorylation levels on a 
range of clinically important cell surface receptors was revealed.  
Results 
It was found that crude venom (A gen., H swa and N Naja) as well as venom fractions 
(A gen.) affected receptor phosphorylation in a time and concentration dependent manner, 
however more experimental research is required to understand the optimal conditions for 
the experiments to be carried out appropriately i.e. venom time incubation, antibody 
treatment.  
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The past, present and future of breast cancer: Venoms as potential new 
therapies targeting the epidermal growth factor receptor family 
 
1.1 Introduction  
Cancer is one of the leading causes of death and disability worldwide (Ferlay et al, 2014).  
In 2015 it accounted for 8.8 million deaths worldwide with breast cancer being accountable 
for 571,000 deaths at this time (World Health Organisation (2015).   
Cancer occurrence is rising in part due to an increasing and aging population but there 
are other factors that are involved in the onset of cancer pathologies which include smoking, 
the increasing segment of overweight population, lack of physical activity, shifting 
reproductive patterns and poor diet (Torre et al, 2015).   
There are many types of malignancies, such as lung, breast, stomach, colorectal, head 
and neck and pancreatic carcinomas.  In fact there are over 200 types of cancer are believed 
to exist (Cancer Research UK (2017). Investigations into the mutations that lead to cancer 
pathogenesis have revealed that these affect a range of regulatory pathways at cellular level 
that end in tumour formation (Cairns, Harris & Mak, 2011). Consequently, the efficacy of 
targeting individual signalling molecules is under scrutiny, as a variety of oncogenic signalling 
pathways are collaborating in order to adapt tumour cell metabolism to ensure growth and 
survival (Cairns, Harris & Mak, 2011).  
The oldest mention of breast cancer known to date was found in an ancient Egyptian 
papyrus, written around 3000 BC. The papyrus is believed to be a textbook on surgery, 
describing breast cancer as having no treatment. However, Hippocrates, who was a Greek 
physician, also known for establishing the foundation for modern medicine, coined the word 
2 
 
carcinoma or carcinos. The term cancer, which was translated by Roman physician Celsus 
from Greek to Latin, translates into crab and the resemblance is due to blood vessels forming 
structures that are similar to crab legs (Hajdu, 2010; Sudhakar, 2009)   
Developments in the field of cancer research and treatment was a slow process, mainly 
because most medical trends established during Galenic, Hippocratic or Dark Ages suggested 
that treating cancer may lead to further suffering and the consensus was that cancer was 
incurable. Although surgery has been established since ancient Egyptian times, the process 
was both painful and raw, leading to more complications and blood loss, which fuelled the 
idea of an incurable disease. It was another Greek physician, Galen, who coined the term 
oncos, which translates into swelling, also is used today to describe experts and specialists in 
the field of cancer.  During the nineteenth and twentieth century, surgery was led into a new 
era, partly due to the newly installed field of anaesthesia and working in a sterilised 
environment.  This allowed classic cancer operations to be undertaken, in particular a key 
breast cancer treatment that is still used today, the mastectomy (American Cancer Society, 
2017).   
 
1.2 Molecular mechanisms and breast cancer phenotypes  
In modern times, to facilitate diagnostic and therapy pathways, breast cancers have 
been classified into subtypes using gene expression analysis. These subtypes have been 
identified and characterised via microarray technology (Tamimi et al, 2012; Sørlie et al, 2001).  
On the other hand, immunohistochemistry and nucleic acid in situ hybridization have 
confidently been used for the past 25 and 15 years respectively, and are considered 
cornerstones in identifying endocrine receptor (a receptor molecule that binds to either 
oestrogen or progesterone hormones) positive or negative and Her-2 amplified or non-
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amplified subtypes, respectively (Pusztai et al, 2006).  The more aggressive tumours are 
associated with the presence of Her-2, making the presence or lack thereof of Her-2 in 
tumours is a relevant prognostic factor and a relevant clinical target (Nahta and Esteva, 2003). 
The main breast cancer subtypes are luminal A, luminal B, Her-2-enriched, basal-like 
breast cancer and normal like breast cancer which is known to represent endocrine receptor 
positive breast tumours (Tamimi et al, 2012; Creighton, 2012).  Zardavas et al (2015) describes 
these subtypes based on the various levels of expression of the biomarker triplet – oestrogen 
Receptor (ER+), Progesterone Receptor and HER2 protein. Luminal A type cancer expresses 
Oestrogen and Progesterone Receptors (respectively ER and PR), with low proliferation index 
and decreased pathological grade. Luminal B tumours are ER and PR positive, are 
characterised by high proliferation rate and diminished response to hormonal treatment. 
HER2-enriched cancers are characterised by overexpression of HER2 gene and are associated 
with relapse and poor prognosis (Zardavas et al, 2015; Liu et al, 2015). Triple negative breast 
cancer (TNBC) also known as basal-like cancer does not express ER, PR or HER2 (Liu et al, 
2015) and there is no well-established targeted therapy for this subtype as of yet (Creighton, 
2012). Triple negative breast cancer subtype is known for is overexpressing EGFR, the first 
member of the Epidermal Growth Factor Receptor family. This subtype is associated with poor 
response to therapy leading to poor prognosis (Zardavas et al, 2015). As such, EGFR is a 
potential target for future drug development endeavours focused on triple negative breast 
cancer management. In a study conducted by Liu et al (2015), the difference between basal 
and HER2 enriched subtypes was investigated via immunohistochemical (Dittadi et al, 1993) 
and statistical analysis. From a clinicopathological point of view, the investigation revealed 
the luminal type breast cancers are less aggressive compared to basal and HER2 enriched 
types. Moreover, basal-like cancers overexpressed more EGFR than all other cancer subtypes 
4 
 
(Liu et al, 2015). The relationship between growth factors and respective oncogenes is evident 
and, as far as EGFR is concerned, it plays an important role in cell growth, proliferation and 
differentiation, since its phosphorylation activates signalling pathways involved in these cell 
processes (Herbst, 2004). In other words, many healthy cells express 4 x 104 to 1 x 105 
receptors per cell, while some breast tumours express up to 2 x 106 receptors per cell (Herbst, 
2004). Other markers used in this study included Ki-67, which is a nuclear antigen with a role 
in cell proliferation, and p53 tumour suppressor gene, with a role in cell transformation and 
characterisation (Liu et al, 2015). The result of the investigation revealed that HER2-enriched 
and basal-like or triple negative breast cancers are more aggressive, given the higher 
expression of EGFR and Ki-67 compared to luminal breast cancer. Claudin-low subtype was 
identified in 2007 and the investigations into hierarchical gene clustering revealed this 
subtype is close related to basal-like subtype (Eroles et al, 2012; Prat and Perou, 2011). 
Up to a study on 78 breast cancer samples (Sørlie et al, 2001), the convention for breast 
cancer classification was rather simple: a basal epithelial-like group, a HER2 overexpressing 
group and a normal-like breast cancer subtype group. By systematically investigating the gene 
expression patters in human breast tumours, Perou et al (2000) found different independent 
gene clusters reflecting the histological variation of breast cancers, such as endothelial cells 
stromal cells, adipose-enriched cells, lymphocytes, T lymphocytes and macrophages.  
 
1.3 The Epidermal Growth Factor Receptor family 
Epidermal Growth Factor Receptor or EGFR is one of the four members of the Epidermal 
Growth Factor Receptor family, comprising of EGFR, HER-2, HER-3 and HER-4. The four genes 
encoding the members of the Epidermal Growth Factor Receptor are c-erbB-2/HER2, c-
erbB3/HER3 and c-erbB4/HER4 (Herbst, 2004). Dysregulation of their activity or the pathways 
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related to these growth factor receptors are present in various cancer pathologies, including 
breast cancer (Lurje and Lenz, 2009; Harbeck et al, 2013).  
Multicellular organisms owe their intricacy and complexity to one particular event in 
evolution: emergence of signalling pathways between cells. These systems are 
communication channels between cells or environment, fine-tuned to receive, interpret, 
follow or create instructions for or from other cells and/or environment. A powerful tool in 
the molecular biology of signalling pathways are cell surface receptors. Receptor tyrosine 
kinases are skilful chaperones for pathways involved in cell proliferation, differentiation and 
other cell processes relevant for the pathobiology of many cancer types (Kovacs et al, 2015).  
One of the hallmarks of cancer as described by Hanahan and Weinberg (2011) is 
sustainable proliferative signalling which is described as a fundamental trait in cancerous 
cells. Breast cancers are the result of clonal expansion events, where daughter cells inherit 
mutations that provide them with a selective advantage (Curigliano and Criscitiello, 2014). 
When investigated via genome wide sequencing, these mutations can reveal their role in the 
selection process, whether they are driver or passenger (not involved in the selective process) 
(Curiglino and Criscitiello, 2014). By disrupting the normal growth and cell division regulatory 
circuits, cancer cells become able to sustain chronic proliferation (Hanahan and Weinberg, 
2011; Stamos, Sliwkowski & Eigenbert, 2002). The signals involved in cell proliferation and 
apoptosis begin with the phosphorylation of cell surface growth factor receptors i.e. the 
epidermal growth factor receptor (EGFR).   
EGF‘ ďeloŶgs to the EƌďB faŵilǇ of ƌeĐeptoƌ tǇƌosiŶe kiŶases ;‘TK͛sͿ aŶd ǁas the fiƌst 
receptor tyrosine kinase to be discovered (Bazley and Gullick, 2005, Herbst, 2004). These cell 
surface receptors possess tyrosine kinase activity and are found exclusively in metazoans 
(Stein & Staros, 2000). The completed human genome revealed 58 of the 90 tyrosine kinase 
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sequences are receptor tyrosine kinases (Kovacs et al, 2015). The 11 ligands identified for 
mammalian EGFR are the Epidermal growth factor (EGF), transforming growth factor-α ;TGF 
αͿ, hepaƌiŶ-binding EGF (HB-EGF), betacellulin, amphiregulin, epiregulin, epigen and the 
ŶeuƌeguliŶs ;N‘G͛sͿ ϭ-4 (Bazley and Gullick, 2005). Initial investigations brought up by the 
discovery of the EGFR provided insight in the mechanisms by which receptor tyrosine kinases 
function and aided scientists in identifying a link between an activated oncogene and cancer 
(Bazley and Gullick, 2005).  
  All receptor tyrosine kinases consist of three main domains: an extracellular domain 
with a ligand binding region, a transmembrane domain and a C-terminal, intracellular domain. 
The intracellular domain comprises of a juxtamembrane region, a catalytic tyrosine kinase 
domain and a carboxyl terminal tail.  
 Fig. 1 – Structure of Epidermal Growth Factor Receptor 
 
EGFRs are transmembrane proteins, which are activated (phosphorylated) following 
binding of the EGF and dimerization of the receptor (Normanno et al, 2006). However, there 
is no known ligand for HER-2 and HER-3 lacks tyrosine kinase activity (Harbeck et al, 2013). 
Both EGFR and EGF are found to be overexpressed in several cancer malignancies such as 
breast cancer but also lung, neck and colorectal to name a few. Scientific investigations show 
that these proteins together are able to induce cell transformations (Normanno et al, 2006). 
Amplification of the EGFR gene and mutations of the EGFR tyrosine kinase domain are 
Extracellular domain 
Cellular membrane 
Juxtamembrane 
Tyrosine Kinase domain 
Carboxyl tale 
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common in various cancer pathologies and receptor tyrosine kinases have been found to be 
overexpressed or mutated in some breast cancer subtypes associated with high mortality 
rates (Normanno et al, 2006, Herbst, 2004, Zhang et al, 2007), such as inflammatory and triple 
negative breast cancer. In terms of activation, EGFR undergoes a series of structural events 
meant to integrate various inputs (signals) and yield several outputs (functions) via signalling 
pathways. The EGFR signalling pathways are involved in a series of important cellular process 
such as growth, proliferation, differentiation and apoptosis. Abnormal oncogenic 
phosphorylation of EGFR or any other member of ErbB family of receptors will disturb the 
normal course of the cellular processes these control. The structure of the cytoplasmic region 
of EGFR consists of three domains. The juxtamembrane domain is required for feedback by 
protein kinase C; the noncatalytic carboxy-terminal tail with the required six tyrosine 
transphosphorylation sites is required for binding to adaptor/effector proteins and finally the 
central tyrosine kinase domain which is  responsible with relaying transphosphorylation of 
the six carboxyl tyrosine residues (Bazley and Gullick, 2005; Kovacs et al, 2015). This region is 
the focus for some targeted therapies (Zhang et al, 2007). The EGFR family of receptor 
tyrosine kinases is known to affect various cellular and physiological processes in breast 
cancer and deregulated EGFR pathways promote tumorigenesis and metastasis ;O͛BƌieŶ et al, 
2014). As such, EGFR overexpression is associated with poor prognosis and differentiation. In 
addition, the phenomenon is more common in triple negative breast cancer (see previous 
section) and inflammatory breast cancer, the two most aggressive breast cancers subtypes 
(Ueno and Zhang, 2011; Eroles et al, 2012). Inflammatory breast cancer is very difficult to 
manage as treatment is lacking appropriate strategies and clinical targets (Van Laere et al., 
2013; Morrow et al., 2017). Although limited by their efficiency and clinical response, there 
are treatment approaches available for triple negative breast cancer, but the consensus 
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dictates there are no standard procedures (Oakman et al, 2010). Treatments include 
anthracyclines, taxanes, platinum based chemotherapeutic agents and bevacizumab in 
European countries (Oakman et al, 2010; Swain et al, 2013). 
Some of the signalling pathways activated by EGFR family are the Ras-Raf-MAPK, 
JAK/Stat and PI3K/Akt/mTOR (Figure 1) pathways (Eroles et al, 2012; Masuda et al, 2012). Any 
imbalance in activation or mediation of these pathways affects a range of cellular and 
physiological processes directly involved in malignant transformation in breast cancer 
(Masuda et al, 2012, Eroles et al, 2012). For instance, mutations associated with the 
PI3K/Akt/mTOR pathway are molecular signatures for aggressiveness and chemoresistance in 
metastatic breast cancer (Guerrero-Zotano et al, 2016). The PI3K/Akt pathway is a mediator 
for mammalian target of rapamycin (mTOR), which influences cell growth and proliferation 
via biosynthesis of proteins, lipids and by limiting catabolic processes (Zaytseva et al, 2012). 
 
 
 
 
 
 
 
 
 
 
 
9 
 
 
 
Phosphorylated 
EGFR 
intracellular 
domain 
Activation of PI3K protein through 
the involvement of PTEN proteins 
Intracellular domain of EGFR 
ADP becomes ATP 
upon phosphorylation 
Nuclear membrane 
Activation of Akt protein 
Gene transcription, resulting in cell 
proliferation, inhibition of apoptosis 
and angiogenesis 
                                            Cell nucleus 
EGF binding to EGFR on the 
extracellular domain of EGFR 
 
Fig. 2 – PI3K/Akt/mTOR pathway  
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EGFR expression in breast malignancies is associated with lack of oestrogen receptors, which 
is often rendering hormonal therapy as ineffective (Curigliano and Criscitiello, 2014). EGFR is 
also a driver for tumour proliferation, meaning the presence of EGFR in breast cancer 
subtypes basal-like, luminal B and normal like is often a poor prognosis hallmark (Eroles et al, 
2012).  
In an investigation by Shi et al in 2012 showed that nuclear EGFR was found to activate 
the cyclin D1 gene, which plays a key role in proliferation regulation, via transcription in the 
cell nucleus. This new pathway is believed to transport EGFR, following binding with EGF, to 
the cell nucleus with the aid of binding co-factor STAT3 or via the integral trafficking from the 
ER to the Nuclear Envelope Transport model (Brand et al, 2013). According to the same study, 
presence of nuclear EGFR and FGFR is associated with proliferation in breast cancers, and can 
be potential prognostic factors (Hsu et al, 2009).  
Adenosine monophosphate AMP-activated Protein Kinase has been observed to inhibit 
the overall development of malignancies, by disabling growth factors from stimulating 
oncogenic processes (Jhaveri et al, 2015). The gaps in knowledge and other underlying issues, 
such as investigation of secondary tumours (Zardavas et al, 2014) push the continuous 
research in the field of breast cancer.    
Another set of recurrent issues in current research focused on oncology related fields 
are increased costs.  Translating research into clinical trials has a low success rate, due to 
factors such as disease type, inadequate or insufficient cell lines or insufficient number of 
experiments (Begley and Ellis, 2012). Available data and literature are the basis for most 
investigations and drug development endeavours, more so regarding novel therapies and 
molecular targets (Begley and Ellis, 2012). Traditional treatment courses of therapy provide 
decent response and survival rates. However, the high grade of non-selectivity of these drugs 
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leads to cytotoxic symptoms and many patients do not tolerate these drugs very well (Esteva, 
2004). Understanding the molecular intricacies of breast cancer is a powerful tool in 
developing novel targeted drugs (Nahta and Esteva, 2003). The purpose of many studies on 
novel therapies is to target the molecular aspects of transformed cells, leading to better 
response rates and less toxicity to normal cells (Esteva, 2004). 
 
1.4 Current therapies  
Traditionally, all types of cancer malignancies have been managed via the three main 
therapies: surgery, chemotherapy and radiotherapy. However, more tailored treatments 
have now been developed for many cancers including breast cancer. These treatments 
include hormonal therapy, antibody therapy and immunotherapy (Adams, 2017).  
In modern medicine, surgery is used in a multidisciplinary setting, to improve prognosis.   
Surgery is employed in early stage disease, when the tumour is accessible and is not affecting 
any vital organs or elements thus limiting its effectives in cases were the tumour spreads 
termed metastasis (Dimitrov et al, 2017). As common practice, a border of healthy tissue is 
removed during the process, to diminish the chances of recurrence. As far as breast cancer is 
concerned, there are two types of surgery.  The first is lumpectomy, which conserves most of 
the breast tissue and removes primary tumours, also known as wide local excision.  The 
second is mastectomy, which is removal of all breast tissue (Ohsumi et al, 2007, Dimitrov et 
al, 2017). Historically, William Stuart Halsted developed radical breast removal as a surgical 
anti-cancer therapy during the nineteenth century. In 1970, clinical trials and new 
developments led to the conclusion that local excisions will be just as effective in treating 
breast cancer, followed by radiation therapy (Dimitrov et al, 2017).   John Collins Warren 
(1778-1856) together with Joseph Colt Bloodgood (1867-1935), two American surgeons, 
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ushered a new trend in surgical treatment of breast cancer by advocating for pre-surgery 
biopsy (Lakhtakia & Chinoy, 2014). Following suit, Sir George Lenthal Cheatle (1865-1951) and 
Dr Max Cutler documented all their findings from performing surgery and biopsies and thus 
creating the first modern textbook of breast cancer (Lakhtakia & Chinoy, 2014). 
Radiotherapy found a niche in the field of cancer treatment following Wilhelm Conrad 
‘oeŶtgeŶ͛s disĐoǀeƌǇ of a Ŷeǁ tǇpe of ƌaǇ, iŶ ϭϴϵϲ. The Ŷaŵe X-ƌaǇ ǁas giǀeŶ siŶĐe ͚ǆ͛ ǁas 
the algebraic symbol for unknown quantity. In the next three years from discovery, x-rays 
were used in cancer treatments. As a result, in 1901 Roentgen was awarded the first Nobel 
Prize in Physics. Soon after the discovery of the x-ray, Pierre and Marie Curie, in France, 
discovered the radioactive potential of uranium and isolated radium. Consequently, radium 
was introduced in the radiation therapy of cancer (Hajdu, 2012). However, radiotherapy in its 
early years was a raw process, consisting of prolonged exposures to radiation, with severe 
side effects, including the onset of malignancies (Hajdu, 2012). The initial machines were not 
very accurate and healthy tissue was often damaged in the process. To alleviate side effects 
caused by prolonged exposure, smaller doses over a short period of time were proposed as 
an alternative. In 1911 Claudius Regaud proved that smaller doses of radiation are just as 
effective but with less side effects and thus fractionated radiotherapy became the norm 
(Connel and Hellman, 2009). In contemporary medicine, radiotherapy is used in palliative 
treatment, as adjuvant to chemotherapy or surgery and to manage and alleviate metastasis 
symptoms. 
  In 1878, Thomas Beatson observed how removing ovaries in mice would stop breast 
milk production. This observation led to an experiment where he removed ovaries in patients 
with advanced breast cancer. In turn, he discovered the stimulating effect of the female 
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ovarian hormone – oestƌogeŶ. BeatsoŶ͛s disĐoǀeƌǇ laid the fouŶdatioŶ foƌ ďoth ŵodeƌŶ 
hormonal therapy and endocrine surgery (Hajdu, 2010; Lakhtakia & Chinoy, 2014).  
Hormonal therapy is effective in cases were the tumours overexpress oestrogen 
receptors. The effects of endocrine therapy are not fully understood for tumours 
overexpressing progesterone receptors. It is mainly used as adjuvant therapy, following 
surgery, to prevent recurrence, secondary tumours or metastasis. It can also be used before 
surgery, to reduce the size of the tumour or when surgery is not an option (Locker et al, 1998). 
Unfortunately, all these options present with their own limitations, highlighting the 
need for novel anti-cancer therapies. These limitations are found in all three traditional lines 
of treatments. For instance, surgical removal of tumours should be carried out on patients 
with non-metastatic cancers (Rashid and Takabe, 2014) however, the role of mastectomy in 
breast cancer is still questioned. It is also believed that removing the primary tumour in a 
metastatic disease can promote proliferation, but the study was not critically evaluated 
(Rashid and Takabe, 2014).   Due to faster multiplication than normal cells, transformed cells 
can acquire resistance to chemotherapeutic agents, making chemotherapy a rather limited 
cancer management strategy (Eroles et al, 2012). Hormonal therapy, on the other hand 
depends on the presence of hormone receptors (HR) in a tumour and is therefore restricted 
to less aggressive tumours, not usually associated with negative clinical outcomes (Eroles et 
al, 2012). 
 
1.5 Targeted therapies  
Tumour microenvironment and molecular subtype dictates the therapy strategy, which 
is the premise for personalised therapy (Curigliano and Criscitiello, 2014). The role the 
members of the Epidermal Growth Factor Receptor Family plays in the onset and evolution 
14 
 
of solid tumours has been widely recognized (Arteaga and Engleman, 2014). Beatson, who 
discovered removal of ovaries in premenopausal women with advanced breast cancer leads 
to tumour regression, was a forerunner of hormone therapy (Locker et al, 1998). 
Tamoxifen was the first agent in a class of drugs called selective oestrogen receptor 
modulators, which was originally developed as an oral contraceptive (Brown, 2009).  The 
mechanism of action of tamoxifen has been described as a partial oestrogen antagonist in 
humans, blocking the effect of oestrogen in the mammary glands by binding to the oestrogen 
ƌeĐeptoƌ alpha ;E‘αͿ ;Waƌd et al, ϮϬϭϰ; BƌoǁŶ, ϮϬϬϵͿ. Adǀeƌse effeĐts iŶĐlude iŶĐƌease iŶ 
occurrence in vein thrombosis or pulmonary embolism (Brown, 2009). Reports describe 
resistance mechanisms acquired by patients treated in the long term with tamoxifen and 
disease relapse (Ward et al, 2014). Tamoxifen resistance in mammary tumours is linked with 
activation of the PKA pathway (Bentin Toaldo et al, 2014).  
Aromatase is an enzyme complex present in the placenta and in the granulosa cell of 
the ovarian follicles (Smith and Dowsett, 2003). The same complex is a catalyst in the 
conversion of androgens into estrogens (Lephart and Simpson, 1991). Hurvitz et al., 2015 
report in breast cancer cell lines to determine drug response of Everolimus but these need 
validating. The first aromatase inhibitor was aminoglutethimide, initially meant as an 
anticonvulsant (Smith and Dowsett, 2003). Due to reports of adrenal insufficiency, the drug 
was withdrawn and redeveloped for use in breast cancer treatment (Smith and Dowsett, 
2003). Following the discovery of aminoglutethimide, new series of aromatase inhibitors have 
been developed, named as first-, second- and third-generation inhibitors, respective to their 
chronological order of discovery (Smith and Dowsett, 2003, Fabian, 2007). Third-generation 
aromatase inhibitors are reportedly associated with better performance, fewer side effects, 
and higher specificity for the aromatase enzyme (Fabian, 2007). In spite of their association 
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with fewer side effects, the use third-generation aromatase inhibitors is linked to hot flushes, 
vaginal dryness, fatigue, nausea and loss of bone mineral density (Fabian, 2007). All third-
generation aromatase inhibitors are subdivided into steroidal and non-steroidal which bind 
to aromatase irreversibly and reversibly, respectively (Fabian, 2007). Anastrozole, letrozole 
and exemestane are all third-generation aromatase inhibitors, which are orally administered 
on a daily basis (Smith and Dowsett, 2003, Fabian, 2007).  
Traditional lines of treatment in cancer management are accompanied by severe 
cytotoxic events due to disruption of several cellular processes present in both normal and 
transformed cells, as these treatments cannot distinguish between cancer and normal cells 
(Arora and Scholar, 2005). Understanding the molecular differences between normal and 
transformed cells is critical in designing drugs and developing treatments with limited 
cytotoxic consequences (Arnedos et al, 2015). Cells found in solid tumours exhibit special 
features compared to normal cells, such as high levels of the EGFR family of cell surface 
growth factor receptors, a dissimilarity, which can be exploited in drug development 
endeavours (Hanahan and Weinberg, 2011). By forming homo or hetero dimers, these cell 
surface receptors undergo internalisation followed by phosphorylation of the intracellular 
tyrosine kinase domain. This in turn will trigger a cascade of signals, ending in alterations 
impacting proliferation, apoptosis and metastasis (Zhang et al, 2007; Herbst, 2004). The first 
rational targeted therapy to exploit the aberrant EGFR presence in transformed cells was 
monoclonal antibody therapy (mAbs) which targets the extracellular domain of the receptor. 
The first monoclonal antibody was found to cause reversible downregulation of the cell 
surface receptors and thus reverse the phenotype of transformed cells grown on soft agar 
(Zhang et al, 2007). The first study was carried out in 1985, on nude mice (Drebin et al, 1986). 
Initially, the scientists immunized mice with the cell line B104-1-1, transformed to express the 
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her2-neu oncogene in order to produce these antibodies (Zhang et al, 2007). However, this 
antibody had reduced affinity for the human homologue of HER-2 (Zhang et al, 2007). A 
human homologue was developed later on -4D5- which had inhibitory effects on breast 
cancer cells through HER-2 expression dependant antibody-dependant cellular toxicity (Zhang 
et al, 2007). To control the immunological aftermath of using mouse antibodies in human 
cancers, a recombinant version was developed, engineered on human framework regions 
(Drebin et al, 1986; Carter et al, 1992, Chowdhury and Ellis, 2014). The humanised version of 
4D5 was named trastuzumab, also known as Herceptin and was approved as appropriate for 
the treatment of metastatic breast cancer (Slamon et al, 2001). The human recombinant 
version of 4D5 had a greater affinity for HER2, its target, and controlled antibody-dependant 
cellular toxicity. Trastuzumab targets the extracellular domain of HER2 (Chowdhury and Ellis, 
2014) and it is mainly used for metastatic breast cancer patients in combination with 
chemotherapeutic agents (Zhang et al, 2007). By binding to the extracellular or IV domain of 
the receptor it prevents proteolytic cleavage of HER2 extracellular domain (Kovacs et al, 
2015). Trastuzumab prevents ligand dependant signalling however cannot prevent ligand 
activated HER-2/HER-3 or HER-2/EGFR, which is believed to be a resistance mechanism 
(Harbeck et al, 2013) 
Cetuximab resulted from efforts to reduce immunogenicity of EGFR-specific 
monoclonal antibodies by making a chimeric antibody version containing the variable region 
of EGFR-specific mAbs and human Immunoglobulin G1 constant region (Zhang et al, 2007).  
Cetuximab has been used as a therapy for triple negative stage IV breast cancer, both on its 
own and in combination with carboplatin (Carey et al, 2012). The Translational Breast Cancer 
Research Consortium carried out the study, as there were no previous investigations done on 
Cetuximab in metastatic breast cancer. Another investigation reports the positive results of 
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Cetuximab and cisplatin together as treatment for triple negative breast cancer (Baselga et 
al., 2013).  
Pertuzumab (Perjeta, Genentech, Inc.) is the first drug of its kind, a new class of HER2 
dimerization inhibitor and it was developed based on the human immunoglobulin G1 
sequence. This particular monoclonal antibody targets the second member of the EGFR 
family, HER2 (Amiri-Kordestani et al, 2014) by preventing dimerization with HER-ϯ ;Dall͛Oƌa, 
2015). Trastuzumab and pertuzumab bind to different epitopes of the HER-2 extracellular and 
are used in combination therapy for HER-2 positive metastatic breast cancer (Swain et al., 
2015, Harbeck et al., 2013). Clinical studies revealed pertuzumab is well tolerated with 
adverse effects such as diarrhoea, rash, asthenia, vomiting, nausea and abdominal pain 
(Harbeck et al, 2013).  
Margetuximab is a chimeric monoclonal antibody targeting the extracellular domain of 
HER-2 receptor. Margetuximab is a modified molecule with enhanced antibody dependant 
cellular toxicity (ADCC) (Perez, Rugo and Vahdat, 2013). This antibody has gone through phase 
I clinical trial, showing positive results and is now entering phase II clinical trial, in which 
patients with metastatic breast cancer will be enrolled (Perez, Rugo and Vahdat, 2013). The 
same authors also report new data for everolimus, an agent targeting the mTOR protein. 
mTOR together with PI3K pathways are associated with endocrine therapy resistance in 
patients with hormone positive tumours (Perez, Rugo and Vahdat, 2013). The potential of 
therapies targeting downstream signalling pathways in breast cancer are being tested 
currently in clinical settings, with promising results, as it is believed these strategies will affect 
tumorigenesis at multiple levels (Brufsky, 2014). Other agents in clinical development include 
glembatumumab vedotin and neratinib (Perez, Rugo and Vahdat, 2013).   
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Another form of targeted therapy includes tyrosine kinase inhibitors, which bind to the 
ATP intracellular binding site of the cell surface growth factors receptors (Opdam et al, 2012).  
 Lapatinib is a tyrosine kinase inhibitor, which affects both EGFR and HER-2 (Opdam et 
al, 2012; Arora and Scholar, 2005). When scientists discovered the role EGFR and HER-2 
played in various types of cancer cellular processes, they also realised cancer patients would 
benefit from treatments inhibiting both of their activity simultaneously (Rusnak and Gilmer, 
2011). Finding the appropriate active compound, 4-anilinoquinazoline (Rana and Sridhar, 
2012; (National Centre for Biotechnology Information, 2017) depended on a series of 
improvements in drug discovery such as novel chemistry, broad kinase screening tests and 
cell testing platforms, which included both EGFR and HER-2 cell lines together with 
appropriate controls (Rusnak and Gilmer, 2011). Lapatinib has potent inhibitory effects on 
both EGFR and HER-2 and thus negatively affects the subsequent pathways involving MAPK 
and AKT pathways. This in turn induces apoptosis in a range of cancers, including breast 
cancer (Zhang et al, 2007). In addition, the combination between trastuzumab and lapatinib 
has proven efficient in tumours overexpressing HER-2 and the use of lapatinib in trastuzumab 
resistant cell lines reduces phosphorylation of the trastuzumab resistant pathways (Rana and 
Sridhar, 2012). Relapse in patients treated with lapatinib is still a subject of research, but a 
few mechanisms have been proposed, such as mutations within the HER-2 receptor, 
mutations and over phosphorylation of the PI3K pathway and over expression of other 
receptor involved in tumorigenesis (Rana and Sridhar, 2012). Clinically, lapatinib has been 
approved in combination with capecitabine for HER2 positive metastatic breast cancer (Geyer 
et al., 2006) and in combination with letrozole for HER2 and hormone receptor positive 
metastatic breast cancer (Rana and Sridhar, 2012). Headache, rash, cold and gastrointestinal 
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symptoms were among the side effects exhibited during treatment with lapatinib (Rana and 
Sridhar, 2012).  
 
1.6 AURORA: the international initiative for the investigation of metastatic breast 
cancer 
Breast cancer treatment and management are not only limited by the effectiveness of 
the existing medicines, but also by the gaps in knowledge. For instance, many investigations 
into the molecular diversity of the tumour have been focused on primary tumours (Zardavas 
et al, 2014). In order to gain more knowledge on the subsequent mutations and changes in 
tumour and cell environment in secondary tumours, a representative number of patients 
need to be involved (Curtis et al, 2012). AURORA is a programme started by Breast 
International Group – (BIG) in order to not only identify mutations and aberrations occurring 
between first and secondary tumours (Zardavas et al, 2014) but also to innovate clinical trials 
by characterising metastatic breast tumours and identifying appropriate clinical targets (BIG, 
2017). One of the goals would be for next-generation sequencing tools to create a smooth 
path towards personalised medicine (Russnes et al, 2011).  
Variations between breast cancer patients and variations within a single tumour have 
been labelled tumour inter- and intra-heterogeneity respectively and the causes for these 
events are not yet fully described as breast cancer tumour progression paths remain 
undefined (Russnes et al, 2011). Tumour heterogeneity is also associated with drug resistance 
(Russness et al, 2011; Fisher et al, 2013). Both intra- and inter-tumour heterogeneity are 
drivers for mutations, leading to metastatic diseases exhibiting new molecular aberrations 
that in turn will affect the course of treatments (Zardavas et al, 2014). Acquired resistance to 
a drug is a response to molecular evolution and selective pressures to various drugs used 
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during the course of treatment (Zardavas et al, 2014).  The programme will include 1300 
initially and will include clinical setting in Europe (Zardavas et al, 2014). Patients who will be 
part of the study will provide at least one metastatic tissue sample, tissue from primary 
tumour, blood, plasma and serum samples. The samples will be subject to DNA and RNA 
sequencing and a dedicated software will report results to clinicians (Zardavas et al, 2014). 
Breast International Group will launch clinical trials in order to identify any emerging clinical 
targets for metastatic breast cancer (Zardavas et al, 2014).  
 
1.6 Alternative molecular biology niches 
The cancer phenotype exhibits a range of critical traits that provide the context for 
development of novel therapies (Sledge & Miller, 2003; Hanahan and Weinberg, 2000). These 
featuƌes oƌ ͞hallŵaƌks͟ aƌe desĐƌiďed ďǇ HaŶahaŶ aŶd WeiŶďeƌg fiƌst iŶ ϮϬϬϬ, ǁheŶ the 
authors initially counted six such traits. Since then, the paper became a landmark in the field 
of oncology (Sledge & Miller, 2003). The authors revised their initial paper and in 2011, 
publishing a second piece of work that not only presents the original hallmarks in more detail 
but also introduces four new traits that emerged as a consequence of progress in research. 
The hallmarks, in no particular order, are as follows: (1) sustaining proliferative signalling, (2) 
evading growth suppressors, (3) activating invasion and metastasis, (4) enabling replicative 
immortality, (5) inducing angiogenesis and (6) resisting cell death, with (7) avoiding immune 
destructions, (8) tumour promoting inflammation, (9) genome instability and (10) 
deregulating cellular energetics introduced in the paper published in 2011 as emerging traits 
(Hanahan & Weinberg, 2011).  
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For instance in the case of breast cancer, scientists are looking at the gene makeup of 
the tumour to determine which genes are switched on and therefore tailor an appropriate 
therapy (Deluche, Onesti and Andre,  2015). 
Systems Biology is another pathway for studying and distinguishing the different breast 
cancer pathologies (Song et al., 2017). This relativity new discipline involves the use of 
mathematical modelling and high throughput technologies with the purpose of identifying 
the right combination of treatments and predict clinical outcome (Yarden and Pines, 2012).  
 
1.7 Venom components as potential EGFR targets 
Since the mammary cancer treatment landscape consists mainly of hydrophobic, 
chemotherapeutic substances that are often accompanied by side effects, poor clinical 
outcomes and acquired resistance (Lage, 2003), the need to look for alternative drugs is 
relevant and vital. Some of the currently used tyrosine kinase inhibitors are also limited in 
clinical strategy in terms of their multiple targets (Appert-Collin et al, 2015).  
Venoms are intricate cocktails of disulphide rich peptides, small molecules and salts 
(Saez et el, 2010, Sannaningaiah et al, 2014). A large number of species from the class 
Arachnida employ venom as either a hunting or defence strategy. Since spiders are present 
in many ecological niches and are successfully adjusted to diverse food availability, their 
adaptive traits and dietary preferences reflect in venom composition. For instance, some 
species from suborder Araneomorphae use a venom rich in insect specific toxins. On the other 
hand, the venom of larger species from suborder Mygalomorphae contains mammalian 
specific toxins (Matavel et al, 2015) as these species feed on larger organisms, such as birds, 
amphibians and small fish. As such, venom composition is species specific (Vassilevski et al, 
2009). Many of the molecules in these venoms have been selected throughout evolution 
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based on their effectiveness in killing or paralysing prey and predators (Sunagar et al.,2014; 
Sunagar and Moran, 2015; Matavel et al, 2015), each species dosing their venom according 
to factors such as sex, nutrition and climate (Vassilevski et al, 2009). Venoms act on both a 
local and systemic level, causing toxicity and dermatological issues at the bite site and 
affeĐtiŶg hosts͛ Ŷeƌǀous, ŵotoƌ aŶd ĐiƌĐulatoƌǇ sǇsteŵs. Hoǁeǀeƌ, ŵaŶǇ ǀeŶoŵs aƌe 
currently recognised for their influence on ion channels, making them ideal candidates in the 
search for new pain killers and analgesics (Trim & Trim, 2013). The reason behind this niche 
filling strategy is the diverse range of systems, surface receptors and channels these toxins 
disturb once entered the host bloodstream. It is the reason why these toxins are ideal 
research subjects for scientific investigations focused on treating neurological disorders, pain 
or cancer (King, 2013).  
Most spider venom compositions comprise of polypeptides and target specific toxins 
which affect vital systems once injected into a host (Calvete et al, 2009). Each venom contains 
over one hundred different biologically active components, making each venom a vast, 
protein diverse media (Vassilevski, 2009). Given the large number of species and the protein 
richness of each secretion, it is estimated that over 12 million peptides are predicted to be 
identified from spider venoms (Saez et al, 2010). This variety and the high specificity exhibited 
by venoms in suborder Mygalomorphae make venomous secretions a novel tool in modern 
pharmacology (Vassilevski, 2009). Consequently, biopharmaceutical community recognizes 
the value of arachnid venom in research.  
Since venoms have been employed in hunting, natural selection has been a driving 
engine for toxin efficacy. Consequently, venom toxins exhibit high levels of affinity for 
molecular targets (King, 2013). The toxins can be classified according to their biological 
activity as neurotoxic, cardio toxic, hemolytic, digestive, hemorrhagic and algogenic (Kumar, 
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2014). Hemotoxins affect red blood cells and target the circulatory system and muscle tissue 
(Kumar, 2014; Tambourgi, D.V., 1994) Neurotoxins affect the central nervous system, 
inhibiting ion movement across cell membrane (Kumar, 2014). Cardiotoxins affect the heart 
and cardiac muscle by binding to particular sites and stopping cardiac muscle contractions 
(Kumar, 2014). The six FDA approved drugs that have been synthesized following research on 
venom target mainly cardiac pathologies and are derived from snake venoms (King, 2013).  
Although spiders are considered the most successful synthesisers of venom, the amounts 
obtained from one extraction were considered scant for any scientific investigations (King, 
2013). Recent advances in the field of omics have allowed for this niche to be slowly filled 
(King, 2013).  
Some compounds are commonly found in venoms, such as alkaloids, terpenes, 
polysaccharides, amino acids and small proteins called peptides. The later are a very 
important part of venom composition as they exhibit catalytic effect, are thermally stable and 
proteolysis resistant (Kumar, 2014). Scorpion, spider and snake are three of the main clades 
with medically relevant venomous secretions. 
Snake venoms, according to its systemic effects, can be: hemotoxic, affecting 
cardiovascular functions and circulatory system; cytotoxic, targeting cellular sites, cellular 
ŵeŵďƌaŶes aŶd affeĐtiŶg sigŶal tƌaŶsduĐtioŶ oƌ ŶeuƌotoǆiĐ, daŵagiŶg foƌ the host͛ Ŷeƌǀous 
system (Vyas et al, 2013, Casewell et al., 2014, Costa, 2014). Unlike spider venoms, snake 
venoms rarely exhibit more than one major system effect, following envenomation. 
Disintegrins are abundant in snake venom and have been utilised in many studies, particularly 
for their role in platelet aggregation, inflammatory action and inhibitory effect on tumour 
cells (Chakrabarty and Chanda, 2015; Thangam et al, 2012).  They have been shown to limit 
the progression of breast cancer when delivered to the tumours using liposomes in a 
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xenograft model (Swenson et al., 2004).  Disintegrins are low molecular weight molecules, 
with varying structure, strength and affinity for various molecular targets and were initially 
found through investigations on viperid venom (Vyas et al, 2013). Suto et al (2005) report the 
identification of two snake-derived Vascular Endothelial Growth Factors, which are a family 
of four proteins with an important role in the creation of new blood vessels in tumours. 
Although similar, both VEGF proteins identified from snake venoms exhibited different 
features, in comparison to other VEGF proteins and to each other (Suto et al, 2005). Osipov 
et al (2014) report the isolation of neurotrophin found in cobra venom. The concentration of 
neurotrophin was found to be as high as 0.5% (Osipov et al, 2014). Both mammalian and 
snake-derived neurotrophin are similar and structure and function, making the costs of 
neurotrophin plummet, given the easy isolation of the protein from snake venom (Osipov et 
al, 2014). Another study reports the interactions between Cerastes Cerastes viper and VEGF 
(Ben-Mabrouk et al, 2016). Two disintegrins found in this species venom have been 
consequently found to have pro-apoptotic effects and down-regulate signalling pathways 
involved in tumorigenesis (Ben-Mabrouk et al, 2016). Al-Asmari et al (2016) investigated the 
effects of snake venom on cell line MDA-MB-231 in a time and concentration dependant 
experimental setting.   
Venoms are valuable in the development of novel drugs (Zambelli et al, 2016).  
 
1.8 Conclusion and perspectives  
Given the drawbacks of all of the current therapies, such as the difficult management 
of triple negative and inflammatory breast cancer (Masuda et al, 2012), the lack of 
appropriate clinical targets in the case of both triple negative and inflammatory breast cancer 
(Carey et al, 2012) and the increasing number of breast cancer occurrence worldwide (Torre 
25 
 
et al, 2015), the field of drug development needs more alternatives to look into for future 
drug design efforts.  Scientific literature is plentiful in examples of investigations made on 
venoms research in different settings and for various purposes. Breast cancer overexpressing 
EGFR is a niche topic, for which more research is needed to overcome the shortcomings of 
current breast cancer management. Most of the drugs derived from venoms target 
cardiovascular or chronic pain according to literature thus allowing the mammary cancer 
management niche yet unfilled. At the same time, there are plenty of ongoing studies on the 
interactions between human cancers and various types of venom.  At the same time, the need 
to identify, describe and understand the effects of venoms and venomous peptides, more 
research is needed. 
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Investigating the effects of venoms on the Epidermal Growth Factor 
Receptor and receptor tyrosine kinases as a potential breast cancer therapy 
 
2.1 Background 
Evolution has ensured the peptides and proteins present in venomous secretions are 
fine-tuned and appropriate for the environment the species are present in (Murao et al, 
2013). All the proteins and other components present in spider venoms are the result of 
roughly 400 million years of evolutionary strategies (Sunagar et al, 2015). These traits make 
venoms an ample collection of high affinity compounds which can potentially be used in drug 
development research. 
Venom derived drugs are present in the current medicinal landscape, with six FDA 
approved drugs and ten more in clinical trials (King, 2013). Early scientific investigations 
regarding venomous compounds were focused only on species with potentially fatal 
secretions (Escoubas et al, 2006), but in ϭϵϴϬ͛s Ŷeǁ ƌeseaƌĐh shoǁed the ǀaƌietǇ of 
pharmacological proteins within the venom of the same species (Adams, 2004).  Venoms have 
been since then studied, mainly as an ion channel and receptor ligands source (Escoubas et 
al, 2006). Peptide based treatments found a niche in drug development (Craik et al, 2012) 
following the need to overcome side effects and resistance occurring in cancer treatments 
based on traditional or targeted therapies (Thangam et al, 2012). Their high specificity and 
high affinity shown in in vivo investigations lead to not only highly potent effects but also to 
fewer side effects (Craik, 2013). With over 10 million predicted bioactive molecules, spider 
venoms are a wealthy collection of potential drug discovery candidates (Saez et al, 2010). The 
consensus is that these biomolecules have had millions of years of evolutionary fine-tuning, 
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making them the stable and complex weapons currently employed against both prey and 
predators (Garrison et al, 2016). A fundamental component of spider venom is the disulphide 
rich peptides and an estimated 0.1% of these peptides have been studied so far (Klint et al, 
2012).  
  Following the long line of general limitations encountered in existing anti-cancer 
therapies such as side effects and resistance, looking at other potential treatments and 
naturally occurring small amino-acid chains protein could provide a scaffold for future 
treatments (Almeida and Stankiewicz, 2016). 
Breast cancer is defined as a heterogeneous disease, comprising of multiple molecular 
entities, with distinctive features (Carey et al, 2012; Koboldt et al, 2012). Some members of 
the Epidermal Growth Factor Receptor family of tyrosine kinases have been identified as key 
regulators of cell growth, transformation and other cellular processes in some breast cancer 
subtypes, including triple negative breast cancer (Jacot et al, 2015). Two of the four members 
of the EGFR family – EGFR and HER-2- have been considered as relevant and attractive clinical 
targets in breast cancer drug discovery (Kele et al, 2012). Moreover, the presence of EGFR is 
considered a marker of triple negative breast cancer subtype (Masuda et al, 2012) which lacks 
both hormone receptors (Progesterone and oestrogen) and HER-2 (Straehle et al, 2012; Jacot 
et al, 2015; Oakman et al, 2010). Existing anti-EGFR and HER-2 therapies include monoclonal 
antibodies such as Trastuzumab, which target the extracellular domain of HER-2, or small 
molecule tyrosine kinase inhibitors such as Lapatinib which targets the intracellular ATP 
binding site of both HER-2 and EGFR (Zhang et al, 2007; Rusnak and Gilmer, 2011). As 
mentioned above, these treatments present their own limitations. For instance, Trastuzumab 
does not properly infiltrate solid tumours and the cost associated with manufacturing the 
recombinant protein are known to be high (Zhang et al, 2007). In the case of the small 
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molecule tyrosine kinase inhibitor Lapatinib, limitations occur in regards to dose and toxicity 
as reported by an investigation focused on the combination of mTOR inhibitor Everolimus and 
Lapatinib in metastatic breast cancer (Rana and Sridhar, 2012).  
Some studies have utilised snake and scorpion venom to investigate their effect on 
breast cancer cell lines (Sikkema et al, 2009; Swenson et al, ϮϬϬϰ; D͛“uze et al, ϮϬϭϬ).  The 
diverse range of venoms produced in nature means that there is a wide array of peptides and 
chemical compounds that can be screened for potential new breast cancer drugs.  The need 
to investigate as many types of venom is as relevant as ever, given a sparse venom peptides 
library and the number of species and types of venom available.  Most of the efforts to 
produce treatment drugs from venoms are focused on producing treatments for the 
cardiovascular system (King, 2013) or treatments that target acid sensing ion channels 
(Zambelli et al, 2016).   
 
2.2 Venom-based drugs and peptides 
Venom systems are present in a diverse range of animals. There are three clades with 
medically important venom compositions: snake, spider and scorpion (Fry et al, 2009). Any 
active peptides within these venoms target all main biological pathways and tissue types 
accessible by bloodstream (Fry et al, 2009). Of the three species of interest, snakes are 
widespread and one of the most often encountered species by humans. Their lethal venom is 
believed to have acted on primate brain and sensory functions (Casewell et al, 2013). Snake 
venom is mainly composed of disintegrins, hemotoxic and cytotoxic small peptides and has 
been shown to degrade tumor tissue (Sarfu-Poku, 2015). On the other hand, arthropods are 
found in most ecosystems on Earth, a flexible trait present in their venom composition as well 
(Almeida and Stanckiewicz, 2016). The most common compounds found in spider venoms are 
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low molecular mass toxins, amino acids, neurotransmitters, disulphide rich peptides, enzymes 
and small non-disulphide bonded peptides. (Almeida and Stanckiewicz, 2016). Scorpion 
venom has made possible the research of potassium voltage-gated ions, due to compounds 
such as polypeptide channel blockers (Kuzmenkov, 2015) and was also found to disrupt 
pancreatic and blood cancers (Al-Asmari, 2017).   
One of the first venom-based drugs was Captopril, marketed under the name Capoten 
(Smith and Vane, 2003). The discovery came about after an extract of the venom of Bothrops 
jararaca called bradykinin potentiating factor was tested on angiotensin converting enzyme, 
an important regulator of blood pressure (Smith and Vane, 2003). Capoten received FDA 
approval in 1980 and became the first venom-based drug, developed to treat hypertension 
(Smith and Vane, 2003).  In 1998, two non-enzymatic compounds eptifibatide and tirofiban 
were introduced on the market (Harvey, 2014). Both compounds were identified and 
discovered due to research carried out on venomous snake species Sistrurus miliarius 
barbouri and Echis carinatus, respectively (Harvey, 2014). Both compounds are used in 
treating heart disorders (Harvey, 2014).  
Thangam et al (2012) report the identification of a disintegrin protein from the venom 
of N Naja, with pro-apoptotic effects on MCF-7 breast cancer cells line. MCF-7 breast cancer 
cell line is an oestrogen-dependent cell line, as opposed to MDA-MB-468 which is oestrogen 
independent (Cos et al, 1998).  
 
2.3 Rationale for use of the venoms in this study 
Acanthoscurria geniculata is a theraphosid species, part of the monophyletic group 
Mygalomorphae. There is literature available detailing the use of Acanthoscurria gomensiana 
as an anti-tumour agent (Soletti et al, 2010). Gomensin (one of the active components of 
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Acanthoscurria gomensiana venom) has been found to affect the MAPK/ERK signalling 
pathway. Protein kinase C and PI3K signalling pathway are also shown to have an involvement 
and consequent tumour cell apoptosis has been detailed (Soletti et al, 2010; Kumar et al, 
2010; Heinen & da Veiga, 2011). However, there is little information on the composition of 
Acanthoscurria geniculata venom and the present investigation will contribute to increasing 
current knowledge on venom effects.  
Naja atra (formerly Naja naja atra) venom was previously studied due to the apoptosis 
inducing effects Cardiotoxin III (an active Naja atra venom component) exhibited on 
JAK2/PI3K signalling pathway. (Lin et al, 2010; Das et al, 2011). Naja naja  venom was chosen 
as  there are investigations detailing  the cytotoxic and apoptosis inducing effects of Naja naja 
venom (Das Gupta et al, 2011; Thangam et al, 2012).  
Heterometrus Swammerdami venom was chosen due to several accounts of Bengalin, 
an active component of Heterometrus bengalensis venom, being an effective apoptogenic 
protein that acts via ERK-MAPK pathways (Das Gupta et al, 2007; Das Gupta et al, 2010; Das 
Gupta et al, 2013). 
The aim of this research is twofold: first to analyse and describe the types of venoms 
used in this research in order to expand knowledge on the subject and second to identify any 
potential clinically active compounds following treatment of the breast cancer cell line MDA-
MB-468 cells with the three types of venom from three different species - Spider, Snake and 
Scorpion - and to investigate fractions of this venom. 
 
2.4 Methods 
For this study human breast cancer cell line MDA-MB-468 were used.  These originated 
from pleural effusion and are known to be oestrogen-independent cells, usually expressing 
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more than 106 EGF receptors per cell (Modjtahedi et al, 1993, Zhang et al, 1991). Basal MDA-
MB-468 cell line forms grape-like structures when grown in vitro (Holliday et al, 2011).  
 
2.4.1 A gen., H swa and N Naja venom extraction 
Venoms for these experiments were supplied by Venomtech Ltd.   Venom extractions 
were carried out at Venomtech Ltd., in a laminar flow hood, under the supervision of trained 
specialists, according to their proprietary methods. Venoms were collected using 
Venomtech's optimised procedures to maintain maximum venom quality in safe and 
controlled conditions. Snakes are 'milked' using the voluntary bite protocol. Invertebrates are 
milked under anaesthesia with electrical stimulation. Following the extraction, the venom was 
either freeze dried or frozen until needed at -20°C. Venom concentration was measured using 
a DS11 spectrophotometer (DENovix, US). Studies with these experiments have not been 
carried out before therefore the concentrations to use in each step had to be optimised 
before the experiments were undertaken.   
 
2.4.2 Mammalian cell culture 
The human breast cancer cell line MDA-MB-468, was originally obtained from ATCC.  
Cells were cultured in 25cm3 culture flasks (Sarstedt, Inc, Newton, USA) and were cultivated 
iŶ DulďeĐĐo͛s ŵodified Eagle͛s ŵediuŵ ;GiďĐo, UK). L-Glutamine (1%), penicillin-streptomycin 
(1%) and Foetal Calf Serum (10%) (all from Invitrogen, Paisley UK) were added to the media. 
Cells were incubated at 37 °C and 5% CO2. To sub-culture the cells when needed, the cells 
were washed twice with sterile Phosphate Buffered Saline pH 7.4 and then incubated in 
Trypsin-EDTA (0.05% trypsin, 0.53 mM sodium EDTA, Invitrogen, Paisley) for 10 minutes. The 
trypsin-EDTA was removed and replaced with 0.2 mL of the same reagent until the cells had 
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detached from the flask. The cells were re-suspended in a total of 5 mL of media after being 
re-aliquoted as required by the experiment carried out. For instance, frozen cell stocks would 
be prepared similarly, but the final trypsin stage would only require 0.1mL of trypsin. The cells 
were re-suspended in 1 mL Dimethyl Sulfoxide 10% (Sigma, Poole, UK) and Foetal Calf Serum 
90%. The mix was then pipetted in a cryotube, left at -20 C overnight and then moved to a -
80oC freezer for long term storage. For indefinite storage, the cryotubes were stored in liquid 
nitrogen.  
 
2.4.3 Bradford assay  
For each of the samples obtained, a Bradford assay was carried out to measure protein 
concentration and thus ensure each sample has the same protein concentration when 
analysed via gel electrophoresis. The protocol was carried out in 96 well plates, with Bovine 
Serum Albumin (Sigma, UK) as a control, used at ϭϬϬμg/ŵl ǁoƌking dilution. Further serial 
dilutions were obtained from the working dilutions, which are outlined in table below. The 96 
well plates were analysed using a BMG Labtech (UK) plate reader. However, samples obtained 
after the treatment with fractions of venom were analysed using a DS 11 spectrophotometer 
to ensure accurate measurements. 
 
2.4.4 Venom treatment and sample preparation 
Venom treatments were carried out using the following protocol. MDA-MB-468 cells 
were trypsinised and plated out in 12 well plates. Cells were grown to at least 70% confluency 
before any treatment was carried out. Venom serial dilutions from 1:10- 1:100000 were 
prepared on the day of the experiment, prior to incubation and were prepared in DulďeĐĐo͛s 
Modified Eagle Media (Gibco, UK). Cells were incubated with venom for 2h at 37oC. After 2h, 
48 
 
the venom was removed and media containing a final concentration of 1x10-7M EGF (Sigma, 
UK) was added to all wells, except for the negative control well. After the 5 min. EGF 
incubation, all the media was removed and the cells were washed with a final concentration 
of 2mM EGTA in PBS pH 7.4 (Sigma, UK). Radioimmunoprecipitation assay (RIPA) buffer was 
prepared and kept on ice, by mixing ϭϬϬϬμl of the buffer, with ϭϬμl each of the protease 
inhibitor cocktail (100x) and phosphatase inhibitor cocktail (100x) and EDTA (100x) (Thermo 
Scientific, UK). The amount of total RIPA buffer was adjusted to make up to 15Ϭμl of ďuffeƌ 
per well. For the venom lysate samples used in the human phospho-array experiment, full 
flasks of MDA-MB-468 cell line were lysed, using the same reagents, but different amounts 
i.e. ϱϬϬμl ‘IPA ďuffeƌ, aŶd ϱμl of the pƌotease aŶd phosphatase iŶhiďitoƌs aŶd EDTA peƌ flask, 
After all the wells were added the 150μl of lǇsis ďuffeƌ oƌ the flasks ǁeƌe added ϱϬϬμl lǇsis 
buffer, the plates or flasks were kept on ice for approx. 5 minutes and checked for total lysis 
i.e. until the consistency has visibly changed. The contents of each well were transferred into 
individual 2mL tubes, appropriately labelled and spun at 4 °C for 10 minutes or at least until 
a pellet became visible. The supernatant was transferred into a fresh tube and the 
appropriate amount of 5x sample buffer was added to make up a final concentration of 1x 
sample buffer. Where the sample required spectrophotometry analysis to determine protein 
concentration, a small amount of the supernatant was transferred into another tube and 
stored at -80 °C. Positive and negative controls were used throughout the experiment, with 
positive control meaning samples were not treated with venom but treated with EGF, and 
negative control meaning samples were treated with neither venom nor EGF.  
Venom samples obtained following fractionation protocol were freeze-dried. The 
fractions were re-suspended in 12 μl ‘NAse and DNAse free water (Thermo Scientific) and 2 
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μl was used to ĐaƌƌǇ out speĐtƌophotoŵetƌǇ ŵeasuƌeŵeŶts. The ϭϬ μl left ǁeƌe fuƌtheƌ 
diluted to ϭ iŶ ϭϬϬ, usiŶg DulďeĐĐo͛s Modified Eagle Media ;GiďĐo, UKͿ.  
 
2.4.5 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
7% and 9% bis-acrylamide (30%, Bio-Rad, UK add info from D) gels were used for these 
experiments, made up following the standard protocol and using Tris HCl 1.5M (Fisher 
Scientific, UK), SDS 10%, distilled H2O, N,N,N,N͛-Tetra-methyl-ethylenediamine (TEMED, Bio-
Rad, UK) and APS 10% (Ammonium persulfate, Fisher Scientific, UK).  The gels were set for 
45min to 1 hr in 0.75mm glass plates. 
A Bio-Rad Mini PROTEAN Tetra Cell (Hemel Hempstead, U.K.) was utilised to run 1D SDS-
PAGE gels. The glass plates for pouring gels were cleaned with ethanol and assembled as per 
supplier instructions. 
The sample amount was chosen carefully, by using the protein concentration in each 
sample, identifying the lowest concentration, allocating the lowest concentration the 
standard amount to analyse through SDS-PAGE i.e. ϭϱμl, diǀidiŶg the loǁest pƌoteiŶ 
concentration by each protein concentration and multiplying by the amount allocated to the 
lowest protein concentration to be analysed through SDS-Page. For experiments with very 
limited amounts of sample, i.e. venom fraction analysis, protein concentration was 
determined using a DS11 spectrophotometer. Alternatively, a 96 well plate Bradford assay 
was used.  After loading, the samples were run at 70V until the molecular weight ladder 
started to separate. The voltage was set to 170 until the dye front reached the bottom of the 
gel. 
Stacking gels were made at a 3.75% concentration. The stacking gel (3.75% 
Acrylamide/Bis solution 29:1, 0.1M Tris/HCL pH 6.8, 0.1% SDS, 0.1% APS, ϭϱ μl TEMED) was 
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poured and allowed to set with either a 0.75mm or 1.5mm thick comb with  5mm width wells 
inserted.  
Gel tanks were filled with 1x running buffer (0.025M Tris, 0.192M glycine, 0.1% SDS, 
pH8.3) (Bio-Rad, Hemel Hempstead, U.K.). The acrylamide gels analysed for the Coomasie 
stain step have been incubated in Coomasie blue stain (Bio-Rad, UK) for an hour and 
destained in 10% acetic acid and 10% methanol overnight. 
 
2.4.6 Immunoblotting 
The gels were placed between three 3mm Whatman filter paper (Maidstone, UK) sheets 
on top and bottom, with a nitrocellulose (Amersham Biosciences, Little Chalfont UK) or PVDF 
membrane (Immobulin, UK) between the gel and the bottom three filter paper sheets. The 
PVDF membrane was first activated by immersion in 100% methanol (Fisher, UK). The filter 
paper and nitrocellulose/PVDF membranes were immersed in semi-dry blotting buffer prior 
to setting on the three-filter paper stack. Two instruments were used to undertake the 
protein transfer step: an Invitrogen semi-dry western blotter or a Bio-Rad transblotter. 
Protein transfer conditions for Invitrogen semi-dry blotter were: 45-60 minutes at 10-15V. 
The Bio-rad transblotter settings were 30 min at 25V, 1A.  The nitrocellulose was stained 
before being with   Ponceau S solution  (0.1% w/v in 5% acetic acid) to ensure appropriate 
protein transfer.  Once the protein transfer was confirmed, the membranes were incubated 
for 1 hour in blocking buffer containing PBS Tween 20 0.1% (Fisher BioReagents, UK) and 5% 
Marvel milk powder. Following the blocking step, the membranes were washed 5 times for 5 
minutes in PBS Tween 20 at 0.1%. The membranes were cut in half, with the top half of one 
blot incubated overnight in PY20 (1/2000) and the top half of an identical blot with F4 
(1/1000) primary antibody, and bottom half incubated in anti-β aĐtiŶ ;ϭ/ϮϬϬϬϬͿ pƌiŵaƌǇ 
51 
 
antibody. The latter was used as a control to ensure protein load concentration is equal. 
Monitoring phosphorylation levels in each sample analysed via SDS-PAGE and Western blot 
was done using anti-phosphotyrosine monoclonal antibody PY20 (Sigma, UK). In this 
experiment, the PY20 antibody was used at a concentration of 0.0005mg/mL.  Actin 
monoclonal antibody was used to determine visually if the protein concentrations in each 
saŵple ǁeƌe eƋual. Foƌ β-aĐtiŶ aŶtiďodǇ, ϭμl of the stoĐk ;Ϭ.Ϯŵg/ŵLͿ ǁas diluted iŶ ϮϬŵL. 
The use of this isoform of actin as a loading control is due to its ubiquity. It is a housekeeping 
protein, meaning it is present in all cells under normal patho-physiological conditions. 
Following the overnight incubation in primary antibody, the blots were washed 5 times for 5 
minutes in PBS in 0.1% Tween 20. After the washing step, the blots were incubated for 1h in 
rabbit anti mouse secondary antibody (1:20000). Enhanced chemiluminescence reagents 
were used to image the blots after the following protocol: solution A: 10 ml 1M Tris pH 8.5, 
90 mM p-coumaric acid (Sigma, UK), 250Mm Luminol (Sigma, UK), dH20 up to 100mL and 
solutioŶ B: ϭϬ ŵL ϭM Tƌis pH ϴ.ϱ, ϲϰ μl ϯϬ%  H202 (Sigma, UK), dH20 up to 100 mL. Both 
solutions are mixed in equal amounts before use on blots in the Chemidoc Touch Imaging 
System. 
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Table 1: Primary and secondary antibodies used in this study 
Primary Antibody Host and Class Target Dilution used at 
PY20  (Sigma, Poole UK) Mouse Monoclonal Phosphotyrosine 1/2000 
F4       (Gullick et al., 1986) Mouse Monoclonal EGFR 1/1000 
CB11  (Abcam, Cambridge UK) Mouse Monoclonal HER2 1/1000 
21N    (Gusterson et al., 1987) Rabbit Polyclonal HER2 1/200 
RTJ-2  (Hunt et al., 1995) Mouse Monoclonal HER3 1/500 
HFR-1 (Srinivasan et al., 1999) Mouse Monoclonal HER4 1/300 
Anti-β-actin antibody (sigma) Mouse Monoclonal β-actin 1/20,000 
Anti-α-Tubulin antibody  
(DM1A clone) (Sigma, Poole UK) 
Mouse Monoclonal α-tubulin 1/5,000 
Secondary antibody Host and class Dilution Used at 
Rabbit antimouse Radish 
Peroxidase (HRP-Tagged)    
Rabbit Monoclonal 1/20,000 
 
2.4.7 Kinome analysis - Phospho-array human receptor tyrosine kinases kit 
The proteome profiler antibody array is procedure that enables the measurement of 
the level of protein phosphorylation in a cell lysate sample. It is different to a normal 
immunoblot as it allows the siŵultaŶeous of seǀeƌal ‘TK͛s. The kit has a range of specially 
formulated buffers and three nitrocellulose membranes coated with 49 specific kinase 
antibodies. It requires the pre-treatment of the cell lysate with protease inhibitors. The 
reagents were left to reach room temperature before using. The nitrocellulose membranes 
were incubated for one hour at room temperature in array buffer 1, which acted as a blocking 
buffer. Cell lysates were diluted to the appropriate concentration -300mg/µl- using array 
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buffer 1. The blocking buffer added initially was aspirated and the cell lysates were added to 
the membranes. As per the instructions, the cell lysates were incubated with the membranes 
overnight at 2-8 C°. This step requires the membranes to be completely submerged in cell 
lysate solution. The following day, the membranes were washed in 1x washing buffer three 
times. The membranes were incubated in 2 mL horse radish peroxidase detection antibody 
for two hours at room temperature. Membranes were washed again following this step. The 
exception from the instructions as per handout is the use of the maximum protein 
ĐoŶĐeŶtƌatioŶ ϯϬϬŵg/μl foƌ the oǀeƌŶight iŶĐuďatioŶ step. The Ŷeǆt daǇ, foƌ the last tǁo 
hours of the incubation step, the remainder of the venom lysate sample was added to the 
blots, to ensure maximum coverage and ensure maximum protein concentration is available. 
The results were analysed using ImageLab software, Bio-Rad.   
 
2.4.8 Epidermal Growth Factor Receptor Family phosphorylation profile 
In order to assess how the venoms affect the expression of the rest of the members of 
the Epidermal Growth Factor Receptors, an assay was conducted on three cell lines that are 
known for expressing HER-2, HER-3 and HER-4 using A gen., H swa and N Naja venoms. The 
cell lines selected were HEK293, which is known to overexpress HER-3, SKBR3, which is known 
to overexpress HER-2 and NIH3T3, which is known to overexpress HER-4. In order to probe 
for the different receptors, the following antibodies were used: RTJ2 for HER-3 receptor 
overexpressing cell line, CB11 for HER-2 receptor overexpressing cell line and HFR1 for HER-4 
receptor overexpressing cell line. Cell lines were grown and subcultured in 6 well plates as per 
the same protocol for MDA-MB-468 cell line, incubated in venom for 2 hours and lysed as per 
the instructions in Venom treatment and sample preparation section above. SDS-PAGE 
analysis was carried out via the instructions in the sections above, using 9% acrylamide gels.  
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2.4.9 Venom fractionation  
A. geniculata venom was fractionated using a two dimensional method. The first 
dimension was ion exchange and the second dimension was reverse phase chromatography. 
Crude venom protein concentration was measured using the DS-11 microspectrophotometer 
(Dynovix, US) and 20 mg of protein is diluted to 100ul in reverse phase buffer A (0.05% 
trifluoroacetic acid [TFA]), centrifuged in a bench top microcentrifuge (Scientific Lab Supplies) 
and injected on to a C18 column with 5um bead size 250mm x 4.6mm column (Vydac). 
Reverse phase HPLC was then performed with a gradient against 80% acetonitrile in 0.045% 
TFA with a gradient from 5-100% (See Table 1).  Peaks were detected by slope and threshold 
changes of absorbance at A280nm by the automated fraction collector. HPLC was performed 
on the Agilent technologies 1100 HPLC system. 
 
 
 
Table 2: Reverse phase HPLC gradient against 80% acetonitrile in 0.04% TFA buffer (%B) 
Time (Minutes) %B 
0 5 
10 5 
20 20 
100 60 
120 100 
130 100 
131 5 
140 5 
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2.4.10 Freeze drying venom  
Fractions were frozen at -50oC in the Virtis Advantage Freeze Drier (Biopharma Process 
Systems, UK) and Vacuum set point of 500 µbar. After 24hrs temperature was gradually 
warmed at 10 °C intervals until final drying at 0 oC. 
2.4.11 ImageLab analysis 
All the western blot images for these experiments were obtained using a Bio-Rad 
chemidoc imaging system (Bio-Rad, UK) and chemiluminescence detection. Analysis made on 
Human Phospho-array kit western blot was undertaken also using the ImageLab software. 
The images were cropped using the Image Tools tab, bands and lanes have been appropriately 
labelled on images using the Lane and Bands tab. The Lane Profile setting will allow 
visualization of the bands and any adjusting to be done before reporting results via the Report 
setting. All the intensity readings were input in an excel file and organised using Insert tab 
and Chart Tool.  
 
2.5 Results 
2.5.1 Evaluation of optimal venom dose to use in Human Phospho-array experiment 
using Western blotting 
In order to establish the effects the A gen., H swa and N naja   venom had on more than 
one receptor tyrosine kinase and to be able to get simultaneous data on all of them, a 
proteome profiler human phosphor-RTK array kit (R&D Systems UK) was used. However first 
the optimal dose to use in the kinome blot had to be determined. Concentrations were chosen 
for the kinome blot by looking at the highest concentration of venom used that did not affect 
the expression of the control actin.  Results revealed the threshold venom concentrations to 
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be as detailed below. All the types of venom were used at the same dilutions from 1 in 10 to 
1 in 1000000 and the wells were labelled from A to F, respectively.  
Although not obvious from the Coomassie stained acrylamide gels (Fig. 1a) the Western 
Blot analysis revealed the protein levels in the 1:100 treatment were much higher than 
protein levels in the 1:10 treatment and the actin levels were not affected. The affect at 1:10 
is possibly the result of potential cytotoxic effects occurring when using A gen. venom on 
MDA-MB-468 human breast cancer cells at a concentration of 3.772 mg/ml. The dilution was 
chosen following the immunoblotting of the anti-β aĐtiŶ primary antibody treated membrane 
(bottom of Fig. 1a).  Therefore, the relevant dilution for Accanthoscurria geniculata 
theraphosidae venom was determined to be 1 in 100, with a concentration of 0.3772mg/ml 
as the highest concentration showed an increase in EGFR phosphorylation in comparison to 
the rest of the dilutions.  
Samples treated with Naja Naja, formerly known as Naja Naja Atra, have also been 
analysed using coomassie stained gels and Western Blots.  Results revealed the protein levels 
in first three samples, meaning dilutions 1 in 10, 1 in 100 and 1 in 1000, were too low to be 
detected via standard methods (Fig. 1b).  The working dilution was determined to be 1 in 
10000, with a protein concentration of 0.003206 mg/ml. The venom concentrations in the 
Fig. 1a  A &B are a polyacrylamide gel of A gen. cell 
lysates. The six wells loaded contain 5 different 
dilutions of the venom as follows: 1 – molecular 
weight marker, 2 – 1/10, 3 – 1/100, 4 – 1/1000, 5 – 
1/10000, 6 – 1/1000000. Lane number 7 is empty. 
After the empty lane, the next well was loaded with 
a positive control and the last lane contains the 
negative control.  
The first blot below the gel images 1 - is the PY20 
antibody treated blot. The last image  2 - is the actin 
antibody treated blot.  These correspond with the 
polyacrylamide gels above.  1 
2 
A                                                 B 
A                                                 B 
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first three samples was also affecting the levels of actin since the protein levels are also too 
low to be detected in the first three lanes of the actin antibody treated blot 2 in Fig. 1a.  
Heterometrus Swammerdami venom treatment results are shown in Fig. 1c. In 
comparison with the positive control, which was a sample of MDA-MB-468 cells treated with 
EGF and no venom, H swa venom treated samples showed no visible difference in the protein 
levels when analysed through coomasie stained gels, moreover, preliminary analysis using 
immune-detection methods showed an increase in phosphorylation levels when compared to 
the positive control. As a result, the working dilution for H swa venom was determined to be 
1 in 10, with a protein concentration of 4.012 mg/ml. 
 
 
 
 
 
 
 
1 
2 
1 
2 
A                                                 B 
A                                                 B 
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2.5.2 Human Phospho-array analysis to determine venom effect on 49 receptor 
kinases   
Fig. 2 below contains the human phosphor-array blots.  Only the blots labelled were 
analysed in this study as the other blots were the work of another student. Each pair of dots 
on each blot represents a human tyrosine kinase receptor. An intense signal is the result of 
high levels of phosphorylation of the respective receptor, in response to venom treatment. 
Equally, less intense signals are represented by receptors with low levels of phosphorylation 
as a consequence of the blots being treated with the venom.  
 
Fig. 2 Human Phospho-array immunoblots. The samples used in the current 
investigation have been labelled accordingly on the side of the image with the venom used 
to treat the immunoblots. The spots on each immunoblot are capture and control 
antibodies to which specific receptor tyrosine kinases bind during the incubation step. 
Treatment with conjugated horseradish peroxidase HRP was used to detect the signal 
(pixel density of each spot) by chemiluminescence. Spots boxed in red are reference spots 
to show the blot is working. Spots boxed in blue are EGFR.      
Positive 
control 
N. naja 
Negative 
control 
H. swa 
A. gen 
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The proteome profiler nitrocellulose membranes were spotted with 49 different 
specific RTK antibodies in duplicate. The signal (pixel density) data was produced using 
ImageLab software, analysing each set of duplicate spots. 
Following the analysis with ImageLab, the human phosphor-array data was organised in 
graph form to aid in explaining the interactions between venoms and receptors.  
 
Fig. 3 above represents the information obtained from analysing the effects of the three 
types of venom analysed on the Fibroblast Growth Factor receptor family. The intensity of 
each pair of dots on each of the five blots included in this investigation has been organised in 
the form of graphs. Positive control blots which have been treated with EGF but not venom 
were also prepared to compare with the venom treated samples. EGF will bind to EGFR and 
the antibody will detect the phosphorylation levels, which in turn is an indication that the 
experiment has worked. In this experiment, the levels of phosphorylation in the positive 
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sample can also be used as comparison in relationship with the levels of phosphorylation in 
the rest of the samples.  
Negative control samples have not been treated with either EGF or venom. This control 
will allow to identify any non-specific binding of the antibody.  
Fig. 3 compares the three venoms and the two control samples (x axis) to signal (y axis) 
exhibited by each pair of dots on the human phosphor-array blots (Fig. 3). By comparing the 
phosphorylation levels in the three venom treated samples to the positive control, all three 
venoms have inhibitory effects on FGF receptors at the concentrations used.  
 
Fig. 4 above represents the levels of phosphorylation in the EGFR family of receptors 
(excluding EGFR) following treatment with the three types of venom.   When compared to the 
positive control the levels of phosphorylation in ErbB2/HER-2 are decreasing following 
treatment with all three venoms. In comparison with the positive control, ErbB3/HER-3 
receptor shows an increase in phosphorylation levels across all three types of venoms. In the 
case of ErbB4/HER-4, N naja and A gen. venoms are inhibiting phosphorylation since the 
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intensity values of A gen. and N naja venoms are below the positive control intensity readings, 
whilst treatment with H swa increased the levels of ErbB4.   
 
Fig. 5, the phosphorylation levels of Platelet-Derived Growth Factor receptors in 
response to venom treatment are presented in graph forms. In comparison to the positive 
control intensity readings, all three types of venoms are inhibiting Flt-3 receptor and PDGF R 
Beta. The levels of phosphorylation in M-CSF receptor are inhibited by N naja venom but not 
by A. gen and H. Swa. SCF-R and PDGF R alpha phosphorylation is inhibited by N.naja  but not 
A.gen and H.Swa.   
 
 
 
Fig. 5 Phosphorylation levels of PDGF receptor family in response to venom treatments 
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Vascular Endothelial Growth Factor plays a significant role in angiogenesis, the creation 
of new blood vessels in solid tumours. Figure 6 above shows how treatment with H swa 
venom increases the phosphorylation levels in all three VEGF receptors. VEGF R2 
phosphorylation levels are increased following treatment with H swa and A gen. venoms.  
 
 
2.5.3 Epidermal Growth Factor Receptor Family profile 
The samples obtained for use on the human RTK profiler immunoblots were run on 
acrylamide gels together with three more cell lysate samples obtained from cell lines 
overexpressing the rest of the Epidermal Growth Factor Receptor family. The cell lines used 
for this experiment were SKBR3, HEK293 and NIH3T3, which overexpress HER-2, HER-3 and 
HER-4, respectively.  
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Fig. 7a shows HER3 expression (in the top blot), Fig. 7b shows HER4 expression (in the 
top blot) and Fig. 7c shows HER2 expression (in the top blot).  The bottom blots are the actin 
loading control.  The resulting blots were not clear enough for an appropriate interpretation 
of the levels of their respective receptors are. Since the blots probed with actin show that 
there are proteins in the samples, the underlying issue could be related to antibody 
optimisation, as all the preliminary work done with PY20 antibody also required optimising. 
Since the immunoblot images in Fig. 7a shows non-specific binding, the blocking step should 
be longer for these particular antibodies. Also, in order to optimise this experiment, more 
attempts at running the protocol are needed.  
 
 
 
Fig. 7a 
 
 
 
Fig. 7b 
 
 
 
Fig. 7c 
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2.5.4 Analysis of changes in expression of EGFR family members shown from human 
proteome profiler immunoblot 
Fig. 8 below shows the results of treating EGFR with the three types of venom used in 
this investigation. The effect of the three types of venom: A gen., H swa and N naja on EGFR 
has been analysed using the results from the human proteome profiler experiment, the data 
organised in Excel and the intensity of the relevant pair of dots plotted in graph form. The 
signals (y axis) measured for the three venoms are in the range of 7000000-9000000 (in 
pixels), with the positive control showing an intensity reading of over 9000000. This is 
potentially the result of minor inhibition of phosphorylation levels. Arguably, it is not known 
yet which domain of the receptor does the venom target, either extracellular or intracellular. 
Should the venoms target the intracellular domain, the venom incubation step should be 
longer or shorter, depending on the effect and the size of the peptides in each individual 
venom sample.  
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2.5.5 Venom Fractionation of A gen.   
 
 
Using High Pressure Liquid chromatography (HPLC), A gen. venom was fractionated. 
This step yielded 19 samples that were incubated with MDA-MB-468 cell lines via the protocol 
in Methods section. The samples obtained following fractionated venom treatment were 
analysed via SDS-PAGE and Western Blot methods. The reason for this step was to assess 
whether there are any peptides in A gen. venom that target specifically the EGF receptor. The 
use of PY20 antibody informed the leǀel of phosphoƌǇlatioŶ ǁithiŶ eaĐh saŵples aŶd β aĐtiŶ 
will show whether the results seen on PY20 antibody treated blots was the result of the 
interaction between venom fraction and receptor or just unequal loading. By comparison with 
positive control lane, some fractions are exhibiting inhibitory effects on EGF receptor.  Figure 
9 is structured in two paƌts, ǁith the PYϮϬ aŶtiďodǇ oŶ top aŶd β aĐtiŶ aŶtiďodǇ oŶ the 
bottom. The loading map for each blot is the following: Top blot lanes 1-6 were loaded with 
fraction 1-6, respectively. The last two lanes have been loaded with positive and negative 
control, respectively. Middle blot lanes 1-8 have been loaded with venom fractions 7-14, 
respectively. The last two lanes have been loaded with positive and negative control. Bottom 
blot, lanes 1-5 have been loaded with venom fractions 15-19 and the last two lanes after the 
gap are the positive and negative control. However, the positive control samples shows up as 
Fig. 9   Venom Fractions Western blots 
A gen. venom was fractionated. The resulting fractions, 19 in total, were 
analysed via SDS-PAGE and western blot methods. The blots have been 
organised starting with PY20 antibody treated blots first (top images), 
followed by β actin antibody treated blots below each PY20 (bottom images).  
1   2   3   4  5   6   7  +   -         8   9   10  11  12  13  14  +   -                  15  16  17 18 19        +    - 
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a very intense band in the bottom blot and is not present on the middle blot. This is potentially 
a transfer issue. The step requires optimisation and therefore multiple runs, which are going 
to be made difficult by the small amounts yielded after venom extractions. A DS11 
spectrophotometer was used to measure the protein concentration in each fraction. 2 μl of 
the re-suspension was used with DS11 spectrophotometer to measure the protein 
concentration. Each sample was measured 5 times and an average was calculated. The 
protein concentration was relevant to make sure the results obtained from PY20 antibody 
treated blots were not the influence of unequal protein concentrations in the samples. Given 
the nature of fractionating protocol, the fractions are freeze-dried. 
 
 
2.5.6 Evaluation of optimal time for venom incubation 
An assay to determine the optimal time for incubating the cells in venoms was carried 
out. The results of the experiment were analysed via SDS-PAGE and Western Blotting. The 
venom used in this step was A gen. The time intervals considered for this experiment were 20 
min, 40 mins, 1hr, 1hr 20 mins, 1hr 40 mins, 2hrs, 2 hrs 30 mins, 3 hrs, 4 hrs 30 mins, 6 hrs, 
24 hrs and 48 hrs. Positive control sample was treated with EGFR but not with venom, and 
the negative control sample was not treated with either EGFR or venom. Positive and negative 
control samples were collected at the 48 hr timepoint. PY20 antibody was used to determine 
the levels of receptor phosphorylation following treatment with A gen. venom. Venom 
dilution used for this experiment was 1 in 100, which was a concentration of 0.3772 mg/ml. 
Table 3 – Fraction concentrations  
Fraction 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
Conc. 
mg/ml 
4
0
.3
6
7
 
1
8
5
.8
3
4
 
2
5
8
.9
8
1
 
3
0
.7
2
0
 
3
.7
9
8
 
3
.5
4
0
 
5
.0
9
8
 
1
3
.4
3
5
 
1
4
.5
3
5
 
1
0
6
.1
1
3
 
5
.5
6
1
 
5
.9
9
1
 
8
.2
4
7
 
6
.7
2
4
 
1
5
.5
7
8
 
1
2
.1
6
1
 
1
1
.5
8
0
 
7
.3
9
6
 
0
.1
7
 
Table 3a (top) and 3b (bottom) A gen. venom fractions protein concentrations 
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The cells were cultured in 12 well plates and allowed to grow until the bottom of each well 
was completely covered with cells. The media used for this step did not contain any Foetal 
Calf Serum, as the proteins in FCS can skew the results by masking the proteins in the samples 
collected. EaĐh ǁell ǁas iŶĐuďated iŶ ϮϱϬ μl of ŵedia, Ŷo FC“ added.  
As shown in Fig. 10, the lanes on the western blot images were labelled from 1-14. Lanes 
8-9 and 15-16 were positive and negative control, respectively. In the same order as 
represented in Fig. 1, the samples represent the following time intervals: 20 minutes-lane 1, 
40 minutes-lane 2, 1 hour-lane 3, 1hr 20 mins-lane 4, 1hr 40 mins-lane 5, 2hrs- lane 6, 2 hrs 
30 mins-lane 7, 3 hrs-lane 10, 4 hrs 30 mins-lane 11, 6 hrs-lane 12, 24 hrs-lane 13 and 48 hrs-
lane 14, respectively. The sample used as positive control has been treated with EGF but not 
with venom to assess the normal phosphorylation levels under the condition imposed by the 
experimental settings. Therefore, positive control lane should have represented the level of 
EGFR phosphorylation in MDA-MB-468 human cancer cell line. However, both negative and 
positive samples have been collected after 48 hours and the possible reason the protein levels 
are too low to be detected via immune-detection is the prolonged exposure to low volume of 
media and the lack of the proteins and nutrients provided normally by FCS. Another reason 
for the results observed would be destruction of cells following extended exposure to venom.  
To determine the appropriate time incubation interval, more research is required. In 
Fig. 10 below, the sample collected after two hours was loaded in the 6th lane. After visually 
analysing the blots in Fig 10, the 2-hour and 2 hour and 30 mins samples showed a clearer 
band with very little protein degradation or receptor breakdown. The ghost bands at the top 
of the blot represent potential non-specific binding of the PY20 antibody.  The aim of this 
experiment was to inform on the best time interval for the breast cancer cells to be treated 
with the venom to interact with the Epidermal Growth Factor Receptor and display the effect 
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on the  phosphorylation levels at different time points. The decision was made difficult by the 
lack of bands in positive and negative control lanes, which could be a result of long incubation 
intervals. The results seen in samples left for 24 hours and 48 hours in lanes 13-14 are 
consistent with positive control lanes 8 and 15, where actin is present in very small amounts 
or not present at all. This can be due to either transfer issues or a consequence of the cells 
being incubated for long intervals, with cells eliminating small molecular weight proteins into 
the media. However, an avenue worth exploring for any future time dependent experiments 
is to have positive and negative controls for every time interval analysed.  
 
 
 
 
 
2.6 Discussion 
The present study investigated the effects of three different venoms from three 
different clades: Spider, Scorpion and Snakes on breast cancer cell line MDA-MB-468. After 
optimisation of the concentrations to be used for the kinome blot the kinome assay was 
undertaken. All the venoms studied had an inhibitory effect on EGFR phosphorylation as 
shown by the kinome blot study. Compared to the positive control, which represented the 
sample treated with EGF but no venom, scorpion venom H.swa had the highest overall 
inhibitory effect.  The least inhibitory effect were recorded on the membranes treated with 
N.naja venom. The overall effect of the H. swa venom is due to the presence of disulphide 
and non-disulfide bridged proteins in its composition, which have a wide range of activities 
such as targeting ion channels, antimicrobial, haemolytic and anticancer effects (Almaaytah 
Fig. 10   Venom Incubation Assay Western Blot treated with PY20 antibody 
(top) and actin (bottom). Time in minutes unless otherwise stated. 
MW    20   40   60    80   100 120  150    +    -                        180  270  360  24hr 48hr         +        -            
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and Albalas, 2014).  Looking at the effects of ErBb2, H. swa had the most obvious inhibitory 
effect compared to positive control readings, followed by N. naja venom and A gen with the 
least inhibitory effects, compared to the scorpion and snake venom. This could be due to the 
presence of proteolytic linear peptides in spider venoms, which would disrupt the cell 
membrane completely and interfere with the cell surface proteins such as EGFR (Kuhn-
Nentwig et al, 2011). Naja species venom has been shown to affect breast cancer cells by the 
activity of a protein called Cytotoxin (Munawar et al, 2017). ErbB2 has the highest presence 
in the positive control compared to the other two members of the EGFR family and as such 
any inhibitory activity of the venoms is of scientific interest.  An inhibitor of HER2 in HER2 
positive breast cancer could potentially lead to a new breast cancer drug. ErbB 3 is present in 
very low amounts in positive control and thus seems to be upregulated by all venoms, more 
so by H. swa. ErbB 4 is inhibited by N. naja venom and upregulated by H. swa venom. A very 
important factor to consider here is that despite various investigations reporting the 
interactions between venomous compounds and cancers, there is not a great deal of work 
done with the MDA-MB-468 breast cancer cell line. Previous investigations focused on MCF-
7, A-431 or He-La cell lines mainly.  
Fibroblast Growth Factor receptor 3, FGFR3 is present in highest numbers according to 
the positive control readings. A. gen venom had the highest inhibitory effect on this protein 
out of the three clades. Fibroblast Growth Factor Receptor FGFR and Vascular Endothelial 
Growth Factor Receptor VEGF are involved in neoangiogenesis – the process by which 
tumours create their own blood vessels (Presta et al, 2005; Turner and Grosse, 2010). 
Targeting any or both these cell surface proteins means more avenues to explore in anti-
cancer treatments. Snake venoms are rich in disintegrins, a diverse range of proteins which 
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disrupt the activity of integrins which in turn regulate key stages in cancer initiation and 
progression (Kele, 2015). 
GiǀeŶ that MǇgaloŵoƌphae speĐies͛ ǀeŶoŵ is ƌiĐh iŶ ŵaŵŵaliaŶ-specific compounds, 
this investigation was relevant by revealing the effect Accanthoscurria geniculata venom had 
on various tyrosine kinase receptors including on the members of the Epidermal Growth 
Receptor Family, which have been a relevant clinical target since their discovery in 1960 (Lo, 
2010).  Spider venoms are also known to contain non-peptide compounds such as inorganic 
salts (Heinen and da Veiga, 2011) and as such more research is needed to identify how these 
various compounds in either crude venom or venom fractions interact with various biological 
targets and what is their nature i.e. peptides or non-peptides. Also, the costs associated with 
designing new drugs can be reduced by looking at naturally occurring molecules (Almeida and 
Stanckowickz, 2016). According to Almeida and Stanckowickz (2016), there are no patent 
applications that involve venom from Accanthoscurria genus. However, venom from 
Accanthoscurria Gomesiana has been used in experimental settings to assess its effects on 
human cancer cell lines, including human breast cancer cell line SKBR3. Since 1986, 76 patent 
applications were filled following spider venom research results (Almeida and Stanckowickz, 
2016).   Accanthoscurria geniculata genome has been recently described to be approx. 6 Gb 
which in turn can prove helpful in investigating venom evolution and toxin selection (Pineda 
et al, 2014). Notably, theraphosidae venom investigations have been facilitated by advances 
in biochemistry tools (Craik et al 2013; Pineda et al, 2014).  
Snake venoms are known to be rich in various compounds such as disintegrins, which 
are believed to disrupt key process in tumors (Kele et al, 2015). Integrins present in tumour 
cells play a role in proliferation, invasion and survival (Kele et al, 2015). Disintegrins are 
capable of binding specifically to integrins and thus interfere with vital tumorigenesis 
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processes (Kele et al, 2015). Thangam et al (2012) describe a disintegrin identified in Naja 
Naja venom with cytotoxic and apoptotic effects on human cancer cell lines in vitro. However, 
this study used MCF-7, HepG2 and A549 cell lines, which show different EGFR densities 
compared to cell line MDA-Mb-468. Investigations on snake venom have been facilitated by 
the amounts venom extractions would yield (King, 2013; Pineda et al, 2014). According to 
Mirtschin et al (2006), some Naja species wet venom ranges between 1.161 and 0.741 grams 
on average. Tarantula milkings usually results in amounts measuring between 2-10 µl. Thakur 
et al (2016) studied the effects of ruviprase, a protein identified in Daboia Russelli venom on 
various human cancer cell lines including MCF-7 breast cancer cell line, which showed the 
apoptosis inducing effects of the protein in a time dependent manner.  
The human proteome profiler assay revealed the effects the venoms had on the level 
of phosphorylation of various receptors. Of particular interest is EGFR.  The phosphorylation 
level graphs in the results section can be used to determine new targets for future breast 
cancer therapies. For instance, PDGF‘β has ďeeŶ liŶked to shoƌteƌ suƌǀiǀal ƌate iŶ ďƌeast 
canĐeƌs ;PaulssoŶ et al, ϮϬϭϲͿ.  PDGF‘α has ďeeŶ assoĐiated ǁith tumour progression in a 
study carried out on MCF-7 and HS578T breast cancer cell lines (Carvahlo et al, 2005). In a 
study carried out on MDA-MB-231 and MDA-MB-157 triple negative breast cancer cell lines, 
PDGF‘β ǁas shoǁŶ to pƌoŵote aŶgiogeŶesis ;D͛Ippolito et al, 2016). Issa et al (2013) carried 
out an investigation on 4T1 and 67NR breast cancer cell lines to determine the efficacy of 
combination targeted therapy which revealed targeting both FGF and EGFR can have 
inhibitory effects on basal-like breast cancers (also known as triple negative breast cancer). 
Neovascularisation in an important process in tumorigenesis following which new, small 
tumours can grow, given the access to nutrients and blood supply (Sitohy et al, 2012). 
However, most clinical trials carried out on targeted VEGFR therapies had little success (Sitohy 
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et al, 2012). In a study carried out Bevacizumab in triple negative breast cancer, the scientists 
reported various adverse events, which led to discontinuation of the clinical trial for most of 
the patients involved in the study (Cameron et al, 2013). Bevacizumab is a monoclonal 
antibody that targets the VEGFR (Cameron et al, 2013). Fig 5 shows the levels of PDFR 
Receptor family. Positive control measurements revealed elevated levels of PDGF R Beta and 
FR 3. PDGFR Beta is inhibited by the activity of the N. naja venom to a higher degree compared 
to A. gen and H. swa. However, M CSF R is upregulated by the activity of H. swa and A. gen 
venom and inhibited only by the activity of N. naja venom. 
A. gen venom was fractionated as there is no available data about this procedure done 
on the venom of this species. The resulting fractions, 19 in total were tested on MDA-MB-468 
cell line. Fractions 1-7 had an obvious inhibitory effect when compared to positive control 
lane. Fractions 8-19 had various effects, with fractions 11, 12 and 18 inhibiting the 
phosphorylation of EGFR and fraction 15 and 19 upregulating phosphorylation of EGFR. 
According to Murao et al (2013), in Acanthoscurria paulensis venom, the first fractions contain 
acylpolyamines and other low molecular mass compunds, which may be responsible for the 
effects of A. gen venom fractions, as see in figure 9. 
Available data has however several limitations: the human phosphor-array experiment 
and Western blot of spider venom fractions were carried only once, due to logistics and 
finance associated restrictions. In ideal conditions, a set of three repeats would have allowed 
a statistical interpretation.  The results do however report findings on previously 
uninvestigated venoms in different experimental conditions.  Given the limitations of both 
targeted and non-targeted cancer therapies and the variety of venoms in nature, researching, 
identifying and describing venomous compounds is an effort worthwhile in medicine. At the 
moment, technical advances and the new focus on naturally occurring peptides are paving 
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the way for venom peptide based drugs (King, 2013), convergence scientists should take more 
advantage of.  
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2.8 Appendix 
Graphs representing the phosphorylation levels in the remaining receptor tyrosine 
kinases (Results Section 1- Evaluation of optimal venom dose to use in Human Phospho-array 
experiment using Western blotting) 
  
 
 
 
0
20000
40000
60000
80000
100000
120000
140000
160000
In
te
n
si
ty
 (
p
ix
e
ls
Receptor levels
HGF Receptor Family
HGFR MSP R
0
50000
100000
150000
200000
In
te
n
si
ty
 (
p
ix
e
ls
)
Receptor levels
Insulin Receptor Family
E13 ALK B17 Insulin R B19 IGF-I R
A gen                                N naja                           H swa 
A gen                                N naja                           H swa 
Appendix 1 above shows the effects of the three venoms on Insulin Receptor Family. 
According to the individual receptor levels in positive control, E13ALK receptor is present 
in highest amounts in cell line MDA-MB-468. A gen had the highest inhibitory activity on 
E13 ALK receptor, compared to the snake and scorpion venoms.  
Appendix 2 above shows the effects of the three venoms on Hepatocyte Growth Factor 
Receptor Family. According to the positive control sample, MSP R is present in highest 
amounts in cell line MDA-MB-468. N naja venom had the highest inhibitory effect on MSP 
R, with a signal of 60000 pixel density.  
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Appendix 3 shows the effects of the three venoms on neutrophin receptors. Present in 
highest amounts in cell line MDA-MB-468is TrkA receptor, according to the levels 
measured in positive control sample. Both A gen and N naja had equally high inhibitory 
effects compared to H swa venom.  
Appendix 4 shows the effects of the three venoms on AXL, which is a cell surface protein. 
According the readings in positive control sample, Mer Receptor in present in highest 
amounts in cell line MDA-MB-468. H swa venom had the highest inhibitory activity on the 
receptor out of the three venoms. 
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Appendix 5 and Appendix 7 show the effect on Ephrin receptors. According to positive 
controls samples in the two graphs, E21 EphA10 and D17 EphA1 are present in highest 
amounts in cell line MDA-MB-468. H swa had the highest inhibitory effect on E21 Epha10. 
D17 EphA1 were inhibited equally by H swa and A gen, but N naja had the highest 
inhibitory effect.  
Appendix 6 shows the effects of the three venoms on three receptor families. D1 Tie-2 
angiopoietin receptor is present in highest amounts in cell line MDA-MB-468. A gen and H 
swa had equally inhibitory effects on D1 Tie-2 receptor, with N naja venom showing the 
most inhibitory activity.  
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Appendix 7 Ephrin receptors 
